Stay updated on Imprime PGG+Pembrolizumab in Melanoma & TNBC Clinical Trial
Sign up to get notified when there's something new on the Imprime PGG+Pembrolizumab in Melanoma & TNBC Clinical Trial page.

Latest updates to the Imprime PGG+Pembrolizumab in Melanoma & TNBC Clinical Trial page
- Check5 days agoChange DetectedThe page’s footer revision/version number was updated from v3.5.2 to v3.5.3, reflecting a minor site release rather than a change to the study record itself.SummaryDifference0.0%

- Check12 days agoChange DetectedPage revision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check20 days agoNo Change Detected
- Check41 days agoChange DetectedAdded revision tag v3.5.0 and removed revision tag v3.4.3.SummaryDifference0.0%

- Check48 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3, reflecting a minor update to the page version. It does not affect the study content.SummaryDifference0.0%

- Check77 days agoChange DetectedRevision updates: added v3.4.2 and removed v3.4.1. These changes are minor and do not affect study content, eligibility criteria, or results; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check84 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Imprime PGG+Pembrolizumab in Melanoma & TNBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Imprime PGG+Pembrolizumab in Melanoma & TNBC Clinical Trial page.